Q1 EPS Estimates for Haemonetics Increased by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Equities research analysts at Zacks Research upped their Q1 2027 earnings per share estimates for Haemonetics in a research report issued to clients and investors on Monday, November 24th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings of $1.19 per share for the quarter, up from their prior estimate of $1.18. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2027 earnings at $1.41 EPS, FY2027 earnings at $5.37 EPS, Q1 2028 earnings at $1.38 EPS and FY2028 earnings at $5.89 EPS.

Several other equities research analysts have also commented on HAE. Needham & Company LLC boosted their price target on shares of Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a report on Friday, November 7th. Weiss Ratings raised shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. BTIG Research restated a “buy” rating and set a $88.00 target price on shares of Haemonetics in a report on Friday, November 21st. Raymond James Financial reiterated an “outperform” rating and issued a $90.00 price target on shares of Haemonetics in a report on Friday, November 14th. Finally, Citigroup reduced their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $79.70.

Haemonetics Stock Performance

HAE stock opened at $80.67 on Thursday. Haemonetics has a 1-year low of $47.31 and a 1-year high of $89.69. The business has a 50-day moving average price of $57.96 and a 200 day moving average price of $63.31. The company has a market capitalization of $3.78 billion, a P/E ratio of 24.67, a PEG ratio of 0.91 and a beta of 0.43. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same period in the previous year, the company posted $1.12 EPS. Haemonetics’s revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.

Institutional Investors Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its holdings in shares of Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after buying an additional 1,678,630 shares during the period. River Road Asset Management LLC lifted its holdings in Haemonetics by 18.7% in the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after acquiring an additional 260,624 shares during the period. Geode Capital Management LLC boosted its position in Haemonetics by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock worth $92,873,000 after purchasing an additional 23,257 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Haemonetics by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after purchasing an additional 26,763 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Haemonetics by 2.3% during the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after purchasing an additional 24,650 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.